Company intelligence / Profile preview

Beckley Psytech

Oxford, Oxfordshire, United Kingdombeckleypsytech.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Beckley Psytech has completed enrollment in a global Phase IIb study of BPL-003, their proprietary intranasal formulation of synthetic 5-MeO-DMT for Treatment Resistant Depression. Initial Phase IIa data showed rapid onset and durable antidepressant effects from a single dose with good tolerability. Topline results from the ongoing Phase IIb trial are expected mid to late 2025. Their second candidate ELE-101, an intravenous formulation of psilocin targeting Major Depressive Disorder, is in early clinical stages with initial results anticipated in the first half of 2024[3][5][6][7][9].

Therapeutic areas: Psychiatry
Modalities: Short-duration psychedelic compounds, including synthetic formulations of 5-MeO-DMT and psilocin administered intranasally or intravenouslyRapid acting psychedelic-based medicines designed for mental health conditions
Industry: Biotech

Drug pipeline

2 assets

BPL-003

Phase 2

Indications: Treatment Resistant Depression, Alcohol Use Disorder

1 more asset in the full pipeline.

Partnerships

Strategic investment and collaboration with atai Life Sciences since January 2024. atai holds a significant ownership stake (~35.5%) and collaborates on digital therapeutics development, commercialization planning, and market access activities[3][6][7].

Beyond the preview

Go deeper on Beckley Psytech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beckley Psytech.